Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from NLS Pharmaceutics ( (NLSP) ) is now available.
On June 17, 2025, NLS Pharmaceutics announced significant progress in its iTOL-102 diabetes program, as the BIRD Foundation approved an additional milestone payment to its partners, Kadimastem and iTolerance, for their co-development of a Type 1 diabetes cell therapy. This approval follows a successful Pre-IND meeting with the FDA, marking a pivotal step toward initiating First-in-Human clinical trials. The financial backing from the BIRD Foundation reflects confidence in the collaboration and the potential of iTOL-102 to offer a functional cure for Type 1 diabetes without lifelong immunosuppression, reinforcing NLS’s strategic positioning in the industry.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders. Founded in 2015 and headquartered in Zurich, Switzerland, the company collaborates with world-class partners and scientists to advance its product candidates.
Average Trading Volume: 285,520
Technical Sentiment Signal: Sell
Current Market Cap: $7.91M
For detailed information about NLSP stock, go to TipRanks’ Stock Analysis page.